(NewsDirect)
Emyria Ltd (ASX:EMD)managing director Michael Winlo runs Proactive through the company’sSeptember quarter highlights. EMD generated $1,034,172 of clinicalbillings - an increase of more than 250% compared to the previousquarter- supported by the acquisition of The Pax Centre. The companyalso successfully recruited first patient into its ethics-approvedMDMA-assisted therapy program as well as secured a local supply ofMDMA to start active dosing.
“One of the reasons we're so interested inhaving this broad clinical service footprint, is so we can undertakeinnovative treatments like MDMA assisted therapy,” Winlo said.
“We've got a trialthat's we kicked that off last quarter and we've alreadystarted dosing with our first patients and that hopefully sets us upto turn this into a clinical service that we can offer to far morepatients once we have the authorised prescriber program off and racingas well.
“We have also made goodprogress as far as drug development is concerned.”
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.